Pacira Pharma (PCRX) Tops Q1 EPS by 4c, provides guidance

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.60, $0.04 better than the analyst estimate of $0.56. Revenue for the quarter came in at $177 million versus the consensus estimate of $172.46 million.

GUIDANCE:

Pacira Pharma sees FY 2026 revenue of $745-770 million, versus the consensus of $760.7 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Lennar Corp. (LEN) Misses Q3 EPS by 10c
• BofA Securities Upgrades HawkEye 360 Inc (HAWK) to Buy, 'Attractive valuation flying below the radar'